Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 October 2022 | Story Edzani Nephalela | Photo Supplied
UFS CTL Teaching and Learning Conference
The University of the Free State (UFS) recently held its annual Teaching and Learning Conference. The theme of this year’s conference was Celebrating excellence in learning and teaching, coinciding with the Centre for Teaching and Learning’s (CTL) 10-year celebrations.

The University of the Free State (UFS) recently held its annual Teaching and Learning Conference which began with three pre-conference workshops on the Bloemfontein Campus on 12 and 13 September and ended with a virtual conference hosted from 14 to16 September 2022.

The aim of the UFS Learning and Teaching Conference is to provide academics and academic support staff the opportunity to showcase their innovative learning and teaching practices within different disciplines, as well as to advance the scholarship of teaching and learning at the institution. The theme of this year’s conference was Celebrating excellence in learning and teaching, coinciding with the Centre for Teaching and Learning’s (CTL) 10-year celebrations. During the pre-conference workshops, the focus was on blended learning, curriculum development, and student engagement. 

Dr Engela van Staden, Vice-Rector: Academic, opened the virtual conference on 14 September. She highlighted that universities contribute to the country’s economy through the type of graduates they produce. Therefore, the lecturers are vital; they must use various learning and teaching strategies and diligently perform their jobs to prepare students for the world of work. 

“We must stay current and grasp new advancements in our discipline and teaching methods. These techniques should also recognise students' diversity and multilingualism. With the new Language Policy, we should ensure that our dominant languages are used in academia in years to come. We are here to assist students in becoming employable graduates, and one of the elements that CTL has embarked on is the support we are receiving from them through various programmes, such as Enterprising your Degree: ePortfolio Development (EDED), which provides our students with platforms to market themselves in many professional fields,” Dr Van Staden said. 

Furthermore, Dr Van Staden emphasised the importance of research in enabling and empowering students to remain relevant. COVID-19 has also demonstrated the importance of the teaching approach and tested its efficacy in the classroom. This has resulted in the UFS moving towards becoming a digitalised institution. She stated that the institution has an agreement with the Free State Department of Health to conduct robotic surgery. She further explained that this is not about replacing academics, but about improving teaching and learning. 

In his welcoming address on the second day of the virtual conference, Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, said that the reduction of the achievement gaps between a diverse group of people over the past decade demonstrates that the UFS is not just talking about innovation, equity, quality, and success, but about walking the talk – practically implementing what they profess, to make a real difference in the lives of the students, and to ensure the relevance of the institution.

“During the COVID-19 pandemic, the effective use of advanced data analytics was one of the contributing factors that enabled us to transition to an online learning and teaching environment successfully. It has allowed us to identify a lack of participation in online tuition, to reach out to individual students at risk, and respond with appropriate support mechanisms – thereby ensuring student success,” Prof Peterson added.

He further explained that Vision 130 commemorates 130 years of the UFS’ existence and is also a strategy to reposition the university for 2034 to ensure stability and clarity for planning and decision-making, while leaving scope for adaptation and agility. This vision will, among other things, promote 
• academic excellence, quality, and impact;
• maximum societal impact with sustainable relationships; and
• a diverse, inclusive, and equitable university.

Sizofunda Ngenkani: The Politics and Voice and Merit Principles in Higher Education

Prof Pearl Sithole, Vice-Principal: Academic and Research on the Qwaqwa Campus – one of the keynote speakers – asked, “What impact does our education have on the world? Consider our social enterprise. This demonstrates that there are stumbling blocks that prevent us from learning. We understand that education is a two-way street – capabilities and quality of access. Much has been done to demonstrate that education is more than a classroom endeavour, yet something must explain why education has failed to have the intended influence in societies. This is targeted at the interaction between society and education, and as academics, we are up to the task to ensure that these issues are solved through various programmes.”

Building future excellence through scholarship, collaboration, and action for impact

In his keynote address, Prof Francois Strydom, Senior Director: CTL, presented some of the strategies that have contributed to CTL’s success since its inception in 2012, despite some of the challenges that institutions of higher learning encountered. 

“Scholarships, collaboration, and action have always been instilled in us. We have integrated higher education research, organisational development, and management literature, considering international and national institutional viewpoints and settings. We acknowledge and promote faculty contributions and the dedication of teaching and learning managers who are supported by deans and academics to enhance the quality of teaching and learning,” said Prof Strydom.
He also emphasised the different programmes and research that contributed to this result. There are 223 national and 52 international conference papers, 288 research reports, two books, 93 articles/book chapters/peer-reviewed conference publications, and 35 postgraduate student supervisions.

Following the conference, the centre will be hosting its annual teaching and learning awards event on 12 October 2022 to recognise and award the excellent work done in learning and teaching at the UFS. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept